Clinical Trial Update: Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating XTR004 as an 18F-labeled PET tracer for diagnosing known or suspected coronary artery disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• XTR004

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Coronary Artery Disease (CAD) | Phase 2 | Status: COMPLETED